Language:

Management of opioid use disorders: a national clinical practice guideline

Canadian Medical Association journal (CMAJ), 2018-03, Vol.190 (9), p.E247-E257 [Peer Reviewed Journal]

Joule Inc. or its licensors ;COPYRIGHT 2018 Joule Inc. ;Copyright Joule Inc Mar 5, 2018 ;2018 Joule Inc. or its licensors 2018 ;ISSN: 0820-3946 ;EISSN: 1488-2329 ;DOI: 10.1503/cmaj.170958 ;PMID: 29507156

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Management of opioid use disorders: a national clinical practice guideline
Author: Bruneau, Julie, MD MSc ; Goyer, Marie-Ève, MD MSc ; Ahamad, Keith, MD ; Poulin, Ginette, MD ; Selby, Peter, MBBS MHSc ; Fischer, Benedikt, PhD ; Wild, T. Cameron, PhD ; Wood, Evan, MD PhD
Subjects: Alcohol ; Analgesics, Opioid - therapeutic use ; Buprenorphine, Naloxone Drug Combination - therapeutic use ; Canada ; Clinical medicine ; Clinical practice guidelines ; Drug addiction ; Drug Overdose - drug therapy ; Drug therapy ; Evidence-based medicine ; Fatalities ; Guideline ; Hospitalization ; Humans ; Internal Medicine ; Methadone ; Narcotics ; Nurse practitioners ; Opioid abuse ; Opioid-Related Disorders - diagnosis ; Opioid-Related Disorders - drug therapy ; Opioids ; Patient admissions ; Pharmacists ; Physicians ; Pregnancy ; Primary care ; Psychotherapy ; Societies, Medical ; Substance abuse treatment ; Vulnerable Populations ; Womens health ; Wood, Evan Rachel
Is Part Of: Canadian Medical Association journal (CMAJ), 2018-03, Vol.190 (9), p.E247-E257
Description: Opioid use disorder is often a chronic, relapsing condition associated with increased morbidity and death; however, with appropriate treatment and follow-up, individuals can reach sustained long-term remission. This guideline strongly recommends opioid agonist treatment with buprenorphine-naloxone as the preferred first-line treatment when possible, because of buprenorphine's multiple advantages, which include a superior safety profile in terms of overdose risk. Withdrawal management alone is not recommended, because this approach has been associated with elevated risks (e.g., syringe sharing) and death from overdose in comparison to providing no treatment, and high rates of relapse when implemented without immediate transition to long-term evidence-based treatment. Here, Bruneau et al discuss management of opioid use disorders.
Publisher: Canada: Joule Inc
Language: English
Identifier: ISSN: 0820-3946
EISSN: 1488-2329
DOI: 10.1503/cmaj.170958
PMID: 29507156
Source: ProQuest One Psychology
GFMER Free Medical Journals
MEDLINE
PubMed Central
Alma/SFX Local Collection
ProQuest Central
DOAJ Directory of Open Access Journals

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Management of opioid use disorders: a national clinical practice guideline

Joule Inc. or its licensors ;COPYRIGHT 2018 Joule Inc. ;Copyright Joule Inc Mar 5, 2018 ;2018 Joule Inc. or its licensors 2018 ;ISSN: 0820-3946 ;EISSN: 1488-2329 ;DOI: 10.1503/cmaj.170958 ;PMID: 29507156

Searching Remote Databases, Please Wait